{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:35:56Z","timestamp":1791909356473,"version":"4.3.4"},"reference-count":25,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunoglobulin M (IgM) multiple myeloma (MM) is a rare disease subgroup. Its differentiation from other IgM-producing gammopathies such as Waldenstr\u00f6m macroglobulinemia (WM) has not been well characterized but is essential for proper risk assessment and treatment. In this study, we investigated genomic and transcriptomic characteristics of IgM-MM samples using whole-genome and transcriptome sequencing to identify differentiating characteristics from non\u2013IgM-MM and WM. Our results suggest that IgM-MM shares most of its defining structural variants and gene-expression profiling with MM, but has some key characteristics, including t(11;14) translocation, chromosome 6 and 13 deletion as well as distinct molecular and transcription-factor signatures. Furthermore, IgM-MM translocations were predominantly characterized by VHDHJH recombination-induced breakpoints, as opposed to the usual class-switching region breakpoints; coupled with its lack of class switching, these data favor a pre\u2013germinal center origin. Finally, we found elevated expression of clinically relevant targets, including CD20 and Bruton tyrosine kinase, as well as high BCL2\/BCL2L1 ratio in IgM-MM, providing potential for targeted therapeutics.<\/jats:p>","DOI":"10.1182\/blood.2021011452","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T17:33:34Z","timestamp":1637256814000},"page":"1980-1985","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["IgM-MM is predominantly a pre\u2013germinal center disorder and has a distinct genomic and transcriptomic signature from WM"],"prefix":"10.1182","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-4040","authenticated-orcid":false,"given":"Abdul Hamid","family":"Bazarbachi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"University Cancer Center of Toulouse, Institut National de la Sant\u00e9, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Szalat","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-0562","authenticated-orcid":false,"given":"Anil Aktas","family":"Samur","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1689-1691","authenticated-orcid":false,"given":"Zachary","family":"Hunter","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-6829","authenticated-orcid":false,"given":"Masood","family":"Shammas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[{"name":"University Cancer Center of Toulouse, Institut National de la Sant\u00e9, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8783-5961","authenticated-orcid":false,"given":"Giovanni","family":"Parmigiani","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-6154","authenticated-orcid":false,"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie Clinique et Th\u00e9rapie Cellulaire, H\u00f4pital Saint-Antoine, INSERM UMRs 938, Universit\u00e9 Sorbonne, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"VA Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-5682","authenticated-orcid":false,"given":"Mehmet Kemal","family":"Samur","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2022041219363570600_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin."},{"issue":"11","key":"2022041219363570600_B2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.21845","article-title":"IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom\u2019s macroglobulinemia","volume":"85","author":"Schuster","year":"2010","journal-title":"Am J Hematol."},{"issue":"12","key":"2022041219363570600_B3","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","article-title":"Genetics of multiple myeloma: another heterogeneity level?","volume":"125","author":"Corre","year":"2015","journal-title":"Blood."},{"issue":"11","key":"2022041219363570600_B4","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood."},{"issue":"4","key":"2022041219363570600_B5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-019-0199-3","article-title":"Deciphering the chronology of copy number alterations in Multiple Myeloma","volume":"9","author":"Aktas Samur","year":"2019","journal-title":"Blood Cancer J."},{"issue":"15","key":"2022041219363570600_B6","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood-2014-09-602565","article-title":"The cellular origin and malignant transformation of Waldenstr\u00f6m macroglobulinemia","volume":"125","author":"P","year":"2015","journal-title":"Blood."},{"issue":"6","key":"2022041219363570600_B7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma [published correction appears in Blood. 2018;132(13):1461]","volume":"132","author":"Walker","year":"2018","journal-title":"Blood."},{"issue":"1","key":"2022041219363570600_B8","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun."},{"issue":"6","key":"2022041219363570600_B9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 mutations and response to ibrutinib in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"373","author":"Treon","year":"2015","journal-title":"N Engl J Med."},{"issue":"6","key":"2022041219363570600_B10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nri1633","article-title":"Transcriptional networks in developing and mature B cells","volume":"5","author":"Matthias","year":"2005","journal-title":"Nat Rev Immunol."},{"issue":"3","key":"2022041219363570600_B11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol."},{"issue":"3","key":"2022041219363570600_B12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nri1572","article-title":"Regulation of plasma-cell development","volume":"5","author":"Shapiro-Shelef","year":"2005","journal-title":"Nat Rev Immunol."},{"issue":"1","key":"2022041219363570600_B13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3816\/CLM.2009.n.007","article-title":"CD27 in defining memory B-cell origins in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"9","author":"Sahota","year":"2009","journal-title":"Clin Lymphoma Myeloma."},{"issue":"3","key":"2022041219363570600_B14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3324\/haematol.2009.017251","article-title":"Pathophysiology of Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"95","author":"Stone","year":"2010","journal-title":"Haematologica."},{"issue":"5","key":"2022041219363570600_B15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/modpathol.2011.213","article-title":"Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities","volume":"25","author":"Braggio","year":"2012","journal-title":"Mod Pathol."},{"issue":"6","key":"2022041219363570600_B16","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood."},{"issue":"17","key":"2022041219363570600_B17","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","article-title":"Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells","volume":"121","author":"Walker","year":"2013","journal-title":"Blood."},{"issue":"13","key":"2022041219363570600_B18","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2013-07-513366","article-title":"MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance","volume":"122","author":"Varettoni","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2022041219363570600_B19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2002-11-3333","article-title":"CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma","volume":"102","author":"Robillard","year":"2003","journal-title":"Blood."},{"issue":"25","key":"2022041219363570600_B20","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med."},{"issue":"6","key":"2022041219363570600_B21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/bjh.15058","article-title":"Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results","volume":"180","author":"Richardson","year":"2018","journal-title":"Br J Haematol."},{"issue":"12","key":"2022041219363570600_B22","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"2022041219363570600_B23","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"2022041219363570600_B24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood."},{"key":"2022041219363570600_B25","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/138\/20\/1980\/1890585\/bloodbld2021011452.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/138\/20\/1980\/1890585\/bloodbld2021011452.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T19:37:38Z","timestamp":1649792258000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/20\/1980\/477930\/IgM-MM-is-predominantly-a-pre-germinal-center"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":25,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,11,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021011452","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]}}}